The updated GRAPPA and EULAR recommendations for the management of psoriatic arthritis: Similarities and differences

This publication has 26 references indexed in Scilit:

• Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial
  Arthritis & Rheumatology, 2019
• Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study
  Journal of the American Academy of Dermatology, 2019
• 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
  Arthritis & Rheumatology, 2018
• Clinical management of psoriatic arthritis
  The Lancet, 2018
• Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
  Journal of the American Academy of Dermatology, 2017
• New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
  Rheumatology, 2017
• Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations
  Nature Reviews Rheumatology, 2016
• European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
  Annals of the Rheumatic Diseases, 2016
• Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis
  Arthritis & Rheumatology, 2016
• Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial
  The Lancet, 2015